-
1
-
-
0012717557
-
-
Jaká rizika při cestách do zahraničí Češi podceňují. Tisková zpráva, Ewing Public Relation, Praha 1
-
Jaká rizika při cestách do zahraničí Češi podceňují. Tisková zpráva, Ewing Public Relation, Praha 1, 2002.
-
(2002)
-
-
-
2
-
-
0012673348
-
-
Aventis Pasteur MSD
-
Caumes E, Travel and Health, Aventis Pasteur MSD 1999; 40-41.
-
(1999)
Travel and Health
, pp. 40-41
-
-
Caumes, E.1
-
3
-
-
0012622596
-
-
Rodes J, Arroyo V, ed.Doyma
-
André FE, Hepburn A, Safary A, dHondt E. Development of an inactivated vaccine against Hepatitis A: Therapy in Liver Diseases,ed. Rodes J, Arroyo V, ed.Doyma. 1992: 33-37.
-
(1992)
Development of an Inactivated Vaccine Against Hepatitis A: Therapy in Liver Diseases
, pp. 33-37
-
-
André, F.E.1
Hepburn, A.2
Safary, A.3
dHondt, E.4
-
5
-
-
0035215767
-
Inactivated Hepatitis A vaccine-induced antibodies: Follow-up and estimates of long-term persistence
-
Van Herck K, Van Damme P. Inactivated Hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol 2001; 63: 1-7.
-
(2001)
J. Med. Virol.
, vol.63
, pp. 1-7
-
-
Van Herck, K.1
Van Damme, P.2
-
6
-
-
0012674881
-
-
FDC Reports, June 30
-
FDC Reports, June 30 1997.
-
(1997)
-
-
-
8
-
-
0012622097
-
Inactivated Hepatitis A vaccine: Immunogenicity, efficacy, safety and review of official recommendations for use
-
André FE, Van Damme P, Safary A, Banatvala J. Inactivated Hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. Exp Rev Vaccines 2002; 1: 9-23.
-
(2002)
Exp. Rev. Vaccines
, vol.1
, pp. 9-23
-
-
André, F.E.1
Van Damme, P.2
Safary, A.3
Banatvala, J.4
-
9
-
-
0037765662
-
Rapid seroconversation rates after first dose of an inactivated hepatitis A vaccine (HAVRIX 1440 EU): Results of a retrospective analyses
-
Florence
-
Van Damme P, Lievens M, Stoffel M, Ngueyn C. Rapid seroconversation rates after first dose of an inactivated hepatitis A vaccine (HAVRIX 1440 EU): results of a retrospective analyses. Proc 3rd Eur Conf Travel Med,2002, Florence.
-
(2002)
Proc. 3rd Eur. Conf. Travel Med.
-
-
Van Damme, P.1
Lievens, M.2
Stoffel, M.3
Ngueyn, C.4
-
11
-
-
0033519040
-
Efficacy of Hepatitis A vaccine in prevention of secondary Hepatitis A infection: A randomised trial
-
Sagliocca L,Amoroso P, Stroffolini T et al. Efficacy of Hepatitis A vaccine in prevention of secondary Hepatitis A infection: a randomised trial. Lancet 1999; 353:1136-9.
-
(1999)
Lancet
, vol.353
, pp. 1136-1139
-
-
Sagliocca, L.1
Amoroso, P.2
Stroffolini, T.3
-
12
-
-
0035377715
-
Antibody response to Hepatitis A vaccine in heathy adults
-
Irwin DJ, Millership S. Antibody response to Hepatitis A vaccine in heathy adults. Commun Dis Public Health 2001; 4: 139-140.
-
(2001)
Commun. Dis. Public Health
, vol.4
, pp. 139-140
-
-
Irwin, D.J.1
Millership, S.2
-
13
-
-
0012621788
-
Immunogenicity of two doses of inactivated Hepatitis A vaccine given at an interval of more than 24 months
-
European Conference on Travel Medicine, Venice
-
Landry P, Tremblay S, Darioli R. Immunogenicity of two doses of inactivated Hepatitis A vaccine given at an interval of more than 24 months. European Conference on Travel Medicine, Venice 1998.
-
(1998)
-
-
Landry, P.1
Tremblay, S.2
Darioli, R.3
-
14
-
-
0034668150
-
Inactivated Hepatitis A vaccine booster given > 24 months after the primary dose
-
Landry P, Tremblay S, Darioli R, Genton B. Inactivated Hepatitis A vaccine booster given > 24 months after the primary dose. Vaccine 2000; 19: 399-402.
-
(2000)
Vaccine
, vol.19
, pp. 399-402
-
-
Landry, P.1
Tremblay, S.2
Darioli, R.3
Genton, B.4
-
15
-
-
0036195452
-
Excellent booster response 4-6 Y after a single primary dose of an inactivated Hepatitis A vaccine
-
Iwarson S, Lindh M, Winderstrom I. Excellent booster response 4-6 Y after a single primary dose of an inactivated Hepatitis A vaccine. Scan J Infect Dis 2002; 34: 110-111.
-
(2002)
Scan. J. Infect. Dis.
, vol.34
, pp. 110-111
-
-
Iwarson, S.1
Lindh, M.2
Winderstrom, I.3
-
16
-
-
0012674882
-
Long-term persistence of cellular immunity towards hepatitis A vaccine (HAV) following HAV vaccination
-
April 9-13, Atlanta
-
Desombere I, Van Herck K, Van Damme P, et al.: Long-term persistence of cellular immunity towards hepatitis A vaccine (HAV) following HAV vaccination. 10th Intern Symp Viral hepatitis and liver disease, April 9-13, 2000, Atlanta.
-
(2000)
10th Intern Symp Viral Hepatitis and Liver Disease
-
-
Desombere, I.1
Van Herck, K.2
Van Damme, P.3
|